IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*
Authors:
- Karl FehnleKFKarl Fehnle
- Helmut OstermannHOHelmut Ostermann
- Joachim KienastJKJoachim Kienast
- Oliver CornelyOCOliver Cornely
- Christoph SalatCSChristoph Salat
- Ralf ÜbelackerRÜRalf Übelacker
- Dieter BuchheidtDBDieter Buchheidt
- Gerhard BehreGBGerhard Behre
- Wolfgang HiddemannWHWolfgang Hiddemann
- Xaver SchielXSXaver Schiel
- 1 May 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 34 (5) , 1319-1325
Abstract
To evaluate the effect of intravenous IgMA-enriched immunoglobulin (ivIGMA) therapy on mortality in neutropenic patients with hematologic malignancies and sepsis syndrome or septic shock. Multiple-center, prospective randomized, controlled study. Six university hospitals in Germany. Patients were 211 neutropenic patients with sepsis syndrome or septic shock after chemotherapy for severe hematologic disorders between 1992 and 1999. Patients received 1300 mL of ivIGMA (7.8 g IgM, 7.8 g IgA, and 49.4 g IgG) infused intravenously within a period of 72 hrs or human albumin according to the same schedule as ivIGMA. All-cause mortality at 28 days, sepsis-related mortality at 28 days, all-cause mortality at 60 days, mortality from septic shock, and mortality from microbiologically proven Gram-negative sepsis and septic shock were recorded. Immunoglobulin had no benefit over human albumin. The 28-day mortality rate was 26.2% and 28.2% in the ivIGMA and control patients, respectively (difference, 2.0% [95% confidence interval, −10.2 to 14.2 percentage points]). Likewise, the 60-day mortality rate did not differ between both arms (29.6% vs. 34.7% in the ivIGMA and control patients, respectively). Mortality rates in patients with sepsis syndrome (17.1% vs. 16.7%) and septic shock (51.9% vs. 54.8%) were also found to be similar between both groups. Intravenous ivIGMA had no beneficial effects in neutropenic patients with hematologic malignancies and sepsis syndrome and septic shock.Keywords
This publication has 33 references indexed in Scilit:
- EFFECTS OF HIGH-DOSE OF INTRAVENOUS IMMUNOGLOBULIN AND ANTIBIOTICS ON SURVIVAL FOR SEVERE SEPSIS UNDERGOING SURGERYShock, 2005
- Polyclonal Immunoglobulin for Treatment of Bacterial Sepsis: A Systematic ReviewClinical Infectious Diseases, 2004
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceIntensive Care Medicine, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Interventional antimicrobial therapy in febrile neutropenic patientsAnnals of Hematology, 1994
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992
- Treatment of Gram-negative septic shock with an immunoglobulin preparationCritical Care Medicine, 1991
- Intravenous immunoglobulins in association with antibioticsCritical Care Medicine, 1988
- Cooperative group of additional immunoglobulin therapy in severe bacterial infections: Results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitisJournal of Molecular Medicine, 1987
- Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-StationJournal of Molecular Medicine, 1986